Pharmacological induction of leukotriene B4-12-hydroxydehydrogenase suppresses the oncogenic transformation of human hepatoma HepG2 cells

  • Authors:
    • Lai Wei
    • Jie Liu
    • X. Chris Le
    • Yifan Han
    • Yao Tong
    • Allan S.Y. Lau
    • Jianhui Rong
  • View Affiliations

  • Published online on: June 16, 2011     https://doi.org/10.3892/ijo.2011.1082
  • Pages: 735-745
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Leukotriene B4-12-hydroxydehydrogenase (LTB4DH) is characterized as a chemopreventive and tumor suppressor gene. The aim of this study was to investigate the pharmaco­logical induction of LTB4DH and potential anticancer activity. Using HepG2 cells as a cellular detector, we successfully isolated the active compounds from the herbs Radix Astragali and Radix Paeoniae Rubra through a bioactivity-guided fractionation procedure. Using various analytical techniques including electronic spray ionization-mass spectrometry (ESI-MS) and nuclear magnetic resonance (NMR), gallic acid (GA) was identified as the active compound from Radix Paeoniae Rubra whereas the active compound from Radix Astragali, designated as RA-C, was also purified to the extent that it is now suitable for further identifi­cation. We found that the active compounds from these two different herbs synergistically induced LTB4DH expression in a dose- and time-dependent manner. A key finding was that commercial GA in combination with purified RA-C attenuated the focus formation and anchorage-independent growth, two indexes of in vitro oncogenic transformation, of HepG2 cells via the induction of LTB4DH expression. Moreover, the combination of GA and purified RA-C significantly induced G2/M cell cycle arrest in HepG2 cells. Our results demon­strated for the first time that GA and purified RA-C suppress the in vitro oncogenic transformation of HepG2 cells via the induction of LTB4DH expression. Importantly, pharmaco­logical induction of LTB4DH represents a potential alternative strategy for the therapy of hepatocellular carcinoma.

Related Articles

Journal Cover

September 2011
Volume 39 Issue 3

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wei L, Liu J, Le XC, Han Y, Tong Y, Lau AS and Rong J: Pharmacological induction of leukotriene B4-12-hydroxydehydrogenase suppresses the oncogenic transformation of human hepatoma HepG2 cells. Int J Oncol 39: 735-745, 2011.
APA
Wei, L., Liu, J., Le, X.C., Han, Y., Tong, Y., Lau, A.S., & Rong, J. (2011). Pharmacological induction of leukotriene B4-12-hydroxydehydrogenase suppresses the oncogenic transformation of human hepatoma HepG2 cells. International Journal of Oncology, 39, 735-745. https://doi.org/10.3892/ijo.2011.1082
MLA
Wei, L., Liu, J., Le, X. C., Han, Y., Tong, Y., Lau, A. S., Rong, J."Pharmacological induction of leukotriene B4-12-hydroxydehydrogenase suppresses the oncogenic transformation of human hepatoma HepG2 cells". International Journal of Oncology 39.3 (2011): 735-745.
Chicago
Wei, L., Liu, J., Le, X. C., Han, Y., Tong, Y., Lau, A. S., Rong, J."Pharmacological induction of leukotriene B4-12-hydroxydehydrogenase suppresses the oncogenic transformation of human hepatoma HepG2 cells". International Journal of Oncology 39, no. 3 (2011): 735-745. https://doi.org/10.3892/ijo.2011.1082